Advanced Search
Contact | Corporate | Help

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Sponsors:
  • Sarah Cannon Research Institute
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Neoplasm, Unknown Primary
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: paclitaxel
  • Drug: carboplatin
  • Drug: bevacizumab
  • Drug: erlotinib
Enrollment:
60

Additional information about NCT00360360.


SourceSolution © 2008-2012